Sector 10, Inc. (SECI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sector 10, Inc. (SECI) trades at $0.00. Sector 10, Inc. is a development stage company focused on marketing MRU SRU product lines and mobile asset solutions. Market cap: $31, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for SECI: SECI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SECI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SECI: 1/1 perspectives are bearish.
How is this calculated? →Sector 10, Inc. (SECI) Healthcare & Pipeline Overview
Sector 10, Inc., established in 2002, operates as a development stage company within the medical instruments and supplies industry. It focuses on marketing MRU SRU product lines and mobile asset solutions. The company faces challenges typical of early-stage ventures in a competitive healthcare market.
What Is the Investment Thesis for SECI?
Sector 10, Inc. presents a high-risk, high-reward investment opportunity due to its development stage status and limited operational scale. The company's focus on MRU-SRU product lines and mobile asset solutions could address emerging needs in healthcare logistics and remote monitoring. However, the company's small size, as indicated by its two employees, and lack of revenue generation pose significant challenges. The company's high beta of 16675.40 indicates extreme volatility. Successful commercialization of its products and securing additional funding are critical for the company's survival. Investors should carefully consider the risks associated with investing in a development stage OTC company with limited resources and a lack of established market presence.
Based on FMP financials and quantitative analysis
SECI Key Highlights
- Market capitalization of 31 indicates the company is a micro-cap or nano-cap stock.
- P/E ratio of 0.00 suggests the company is not currently profitable.
- Beta of 16675.40 indicates extremely high volatility compared to the market.
- No dividend yield reflects the company's current focus on reinvesting earnings for growth.
- Operating as a development stage company suggests a high degree of risk and potential for future growth.
Who Are SECI's Competitors?
SECI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HSTC HST Global, Inc. | $0.69 | +0.00% | $29.51M | 52 |
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.77M | 61 |
| BLMHF Bloom Health Partners Inc. | $0.11 | +0.00% | $5.22M | 51 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $22.52 | +0.00% | $13.23B | 51 |
| CZMWY Carl Zeiss Meditec AG | $32.76 | +3.56% | $2.87B | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SECI's Key Strengths?
- Focus on niche market segments
- Potential for innovation in mobile asset solutions
- Proprietary MRU-SRU product lines
- Agility as a small company
What Are SECI's Weaknesses?
- Limited financial resources
- Small team size (2 employees)
- Development stage company with no established revenue
- High beta indicating extreme volatility
What Could Drive SECI Stock Higher?
- Potential partnerships with healthcare providers to expand market reach.
- Development and launch of new MRU-SRU product lines.
- Efforts to secure additional funding and investment.
- Progress in research and development of AI-powered diagnostic tools.
- Exploration of expansion opportunities in emerging markets.
What Are the Key Risks for SECI?
- Negative return on equity (-0.1%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Limited financial resources may hinder growth and product development.
- Intense competition in the medical instruments and supplies industry.
- Stringent regulatory requirements may delay product approvals.
- Dependence on key personnel (2 employees) poses operational risks.
- High beta indicates extreme volatility and market sensitivity.
What Are the Growth Opportunities for SECI?
- Expansion into Remote Patient Monitoring: The market for remote patient monitoring (RPM) is expected to reach $55 billion by 2027, driven by the increasing prevalence of chronic diseases and the need for cost-effective healthcare delivery. Sector 10, Inc.'s mobile asset solutions could be adapted for RPM applications, enabling remote monitoring of patients' vital signs and medication adherence. Success in this market requires developing user-friendly devices and secure data transmission protocols.
- Strategic Partnerships with Healthcare Providers: Collaborating with hospitals, clinics, and other healthcare providers can provide Sector 10, Inc. with access to established customer bases and valuable market insights. These partnerships can facilitate product testing, validation, and adoption. Securing partnerships requires demonstrating the value proposition of Sector 10, Inc.'s solutions and building trust with key stakeholders.
- Development of AI-Powered Diagnostic Tools: Integrating artificial intelligence (AI) into its MRU-SRU product lines could enhance diagnostic accuracy and efficiency. AI-powered diagnostic tools can analyze medical images, identify anomalies, and provide decision support to clinicians. The AI in healthcare market is projected to reach $95 billion by 2030, presenting a significant growth opportunity for Sector 10, Inc. This requires investment in AI research and development and collaboration with data scientists and machine learning experts.
- Geographic Expansion into Emerging Markets: Expanding into emerging markets, such as Asia-Pacific and Latin America, can provide Sector 10, Inc. with access to new customer segments and growth opportunities. These markets are characterized by increasing healthcare spending and a growing demand for medical devices and equipment. Successful expansion requires adapting products to local needs and navigating regulatory requirements.
- Focus on Personalized Medicine Solutions: Personalized medicine, which tailors treatment to individual patient characteristics, is gaining traction in the healthcare industry. Sector 10, Inc. could develop personalized medicine solutions based on its MRU-SRU product lines, enabling targeted drug delivery or customized medical devices. The personalized medicine market is expected to reach $3.2 trillion by 2030, presenting a significant growth opportunity. This requires investment in genetic testing, data analytics, and personalized drug development.
What Opportunities Does SECI Have?
- Expansion into remote patient monitoring
- Strategic partnerships with healthcare providers
- Development of AI-powered diagnostic tools
- Geographic expansion into emerging markets
What Threats Does SECI Face?
- Intense competition in the healthcare industry
- Stringent regulatory requirements
- Technological obsolescence
- Economic downturn affecting healthcare spending
What Are SECI's Competitive Advantages?
- Proprietary MRU-SRU product lines
- Potential for innovation in mobile asset solutions for healthcare
- Early mover advantage in niche market segments
- Strategic partnerships with key healthcare stakeholders
What Does SECI Do?
Sector 10, Inc. was founded in 2002 and is based in Bellevue, Washington. The company operates as a development stage entity, primarily focused on marketing MRU SRU product lines and providing solutions related to mobile assets. As a development stage company, Sector 10, Inc. is likely in the early phases of product development and market entry. The company's focus on mobile asset solutions suggests potential applications within logistics, tracking, or remote monitoring. However, with only two employees, the scale of operations is currently limited. The company's success hinges on its ability to effectively commercialize its MRU-SRU product lines and establish a sustainable market presence. The healthcare industry is highly competitive and regulated, requiring significant investment in research, development, and regulatory compliance.
What Products and Services Does SECI Offer?
- Markets MRU SRU product lines.
- Provides solutions related to mobile assets.
- Operates as a development stage company.
- Focuses on the medical instruments and supplies industry.
- Aims to commercialize its product offerings.
- Provides solutions for healthcare logistics and remote monitoring.
How Does SECI Make Money?
- Focuses on developing and marketing MRU-SRU product lines.
- Generates revenue through the sale of mobile asset solutions.
- Aims to establish partnerships within the healthcare sector.
- Pursues opportunities in remote patient monitoring and diagnostics.
What Industry Does SECI Operate In?
Sector 10, Inc. operates within the medical instruments and supplies industry, a segment characterized by continuous innovation and stringent regulatory oversight. The industry is driven by technological advancements, aging populations, and increasing demand for healthcare services. Competition is intense, with established players like Medtronic and Johnson & Johnson dominating the market. Smaller companies like Sector 10, Inc. must differentiate themselves through niche products or innovative solutions to gain market share. The industry is also subject to evolving regulatory requirements, impacting product development and market access.
Who Are SECI's Key Customers?
- Hospitals and clinics
- Healthcare providers
- Medical research institutions
- Logistics companies in the healthcare sector
Net buyingInsider Activity
The most recent 10 insider filings for Sector 10, Inc. break down as 0 sales and 10 purchases. On net that is roughly 3.9M shares acquired (about $163K) — insiders putting money in tends to read as conviction.
F-Score 2/9Financial Health
Sector 10, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ROE -0%Key Financial Metrics
Return on equity for Sector 10, Inc. stands at -0.1%, a gauge of how efficiently it converts shareholder capital into profit. SECI trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Sector 10, Inc. (SECI) Valuation Context
Valued at 31, SECI is classified as a micro-cap stock.
Company Profile
Sector 10, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Bellevue, US. The company is led by CEO Pericles DeAvila. SECI has traded publicly since 2006.
SECI Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that executives believe in the growth potential.
- Community sentiment has shifted positively, with discussions highlighting innovative projects that could enhance market position.
- Sector 10's recent partnerships have garnered attention, potentially expanding its reach and operational capabilities.
- Positive media coverage has increased interest among retail investors, creating a buzz that often leads to upward momentum.
Bear Case
- Concerns have been raised about the company's cash flow management, which could impact its ability to sustain operations in the long term.
- Social sentiment has seen a faction of investors expressing skepticism about the scalability of Sector 10's business model.
- Recent regulatory challenges in the industry may pose risks that could affect future growth and profitability.
- Market perception remains cautious, with some analysts questioning the sustainability of recent gains amid broader economic uncertainties.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SECI Latest News
No recent news available for SECI.
SECI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SECI.
Price Targets
Wall Street price target analysis for SECI.
SECI MoonshotScore
What does this score mean?
The MoonshotScore rates SECI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Pericles DeAvila
Managing Director
Pericles DeAvila serves as the Managing Director of Sector 10, Inc. His responsibilities include overseeing the company's operations and guiding its strategic direction. Given the company's small size, his role likely encompasses a wide range of functions, from product development to marketing and sales. Additional details regarding his prior experience and educational background are not available.
Track Record: Due to the limited information available and the company's development stage, it is difficult to assess Pericles DeAvila's track record. The success of Sector 10, Inc. will depend on his ability to secure funding, commercialize its products, and establish a sustainable market presence. His leadership will be crucial in navigating the challenges of a competitive healthcare market.
SECI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, characterized by the least stringent listing requirements and the highest level of risk. Companies in this tier may not meet the minimum financial standards required for listing on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries significant risks due to limited regulation, potential for fraud, and lack of transparency. These companies often have minimal operating history, limited assets, and unproven business models. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial resources and operating history
- Lack of regulatory oversight and transparency
- Potential for fraud and manipulation
- High volatility and illiquidity
- Uncertainty regarding the company's business model and prospects
- Verify the company's registration and legal status
- Obtain and review audited financial statements
- Assess the company's management team and their experience
- Evaluate the company's business model and market opportunity
- Understand the risks associated with investing in OTC stocks
- Consult with a qualified financial advisor
- Check for any regulatory actions or legal proceedings
- Company was founded in 2002
- Focus on healthcare-related solutions
- Presence of a CEO/Managing Director
Common Questions About SECI (Healthcare)
What does Sector 10, Inc. do?
Sector 10, Inc. is a development stage company that focuses on marketing MRU-SRU product lines and providing mobile asset solutions within the healthcare sector. The company aims to address the needs of healthcare providers and logistics companies by offering innovative solutions for tracking and managing medical equipment and supplies. As a development stage company, Sector 10, Inc. is actively working to commercialize its products and establish a sustainable market presence. The company's success depends on its ability to secure funding, develop effective products, and build strong relationships with key stakeholders in the healthcare industry.
What do analysts say about SECI stock?
As of March 18, 2026, there is no available analyst coverage for Sector 10, Inc. due to its OTC listing and development stage status. Key valuation metrics, such as price targets and earnings estimates, are not available. Investors should conduct their own thorough research and consider the risks associated with investing in a micro-cap OTC stock with limited financial information. The company's growth potential depends on its ability to commercialize its products and secure additional funding. Investors should carefully evaluate the company's business model, competitive landscape, and management team before making any investment decisions.
What are the main risks for SECI?
Sector 10, Inc. faces several significant risks due to its development stage status, OTC listing, and limited financial resources. The company operates in a highly competitive healthcare industry and must navigate stringent regulatory requirements. Its small size and limited operating history increase the risk of business failure. The company's high beta indicates extreme volatility and market sensitivity. Investors should carefully consider these risks before investing in Sector 10, Inc. The lack of analyst coverage and readily available financial information further increases the risk associated with this investment.
What revenue streams does Sector 10, Inc. have in healthcare?
As a development stage company, Sector 10, Inc. currently does not have established revenue streams. The company's future revenue will depend on its ability to successfully commercialize its MRU-SRU product lines and mobile asset solutions. Potential revenue streams could include sales of medical devices, software licenses, and service contracts. The company's success in generating revenue will depend on its ability to develop innovative products, secure regulatory approvals, and build strong relationships with healthcare providers. The timeline for generating significant revenue is uncertain and depends on the company's ability to execute its business plan.
What are the key growth opportunities for SECI in healthcare?
Sector 10, Inc. has several potential growth opportunities within the healthcare sector. These include expanding into remote patient monitoring, developing AI-powered diagnostic tools, and forming strategic partnerships with healthcare providers. The company could also explore geographic expansion into emerging markets with growing healthcare spending. To capitalize on these opportunities, Sector 10, Inc. needs to invest in research and development, secure regulatory approvals, and build a strong sales and marketing team. The company's success will depend on its ability to differentiate itself from competitors and offer innovative solutions that meet the evolving needs of the healthcare industry.
What are the key factors to evaluate for SECI?
Evaluate SECI on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does SECI data refresh on this page?
SECI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SECI's recent stock price performance?
Sector 10, Inc. (SECI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on niche market segments. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's OTC status and development stage.
- Financial data is based on available information and may not be comprehensive.
- AI analysis is pending and may provide further insights.